THERAPY DOSSIER · th-6dbe2d0e9399

Cyclic AMP

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 2984717 ↗1985Reported benefit

Comparison of cAMP with other radioprotectors against chronic damage to the rat parotid gland.

RatRadiationFemale

Model: Radiation injury of the parotid gland, assessed in acute (first week) and chronic (60 to 90 day) phases

Cyclic AMP protected the parotid gland during the acute phase and remained protective against chronic damage, with a dose modification factor of 1.86 for gland weight. Chronic damage was about 1.5 times as great as acute damage, and protection against acute and chronic damage was approximately equa…

Extraction: extract · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.

Loading the evidence…